Literature DB >> 14755066

Smallpox: clinical features, prevention, and management.

Roy Guharoy1, Robert Panzik, John A Noviasky, Edward P Krenzelok, Donald C Blair.   

Abstract

OBJECTIVE: To describe a general overview of smallpox, clinical presentation, diagnosis, adverse events, and management of both pre- and postexposure vaccination. DATA SOURCES: Literature was identified by search of MEDLINE (1966-June 2003) and International Pharmaceutical Abstracts (1966-May 2003) databases using the key terms smallpox, bioterrorism, biological warfare, and smallpox vaccine. STUDY SELECTION AND DATA EXTRACTION: Articles identified from data sources were evaluated, and relevant information was included in this review. DATA SYNTHESIS: Smallpox is spread by human-to-human contact with an infected host and therefore can be contagious. The mortality rate for smallpox is approximately 30%. While the disease was completely eradicated by 1980 with successful use of smallpox vaccine, concern has been raised that smallpox may emerge as a tool of bioterrorism. This concern, combined with the reality of current smallpox vaccination programs in the military and selected civilian populations, mandates a clear understanding of vaccination-related adverse events and contraindications by all healthcare professionals. The vaccine may cause moderate to severe adverse events such as eczema vaccinatum, progressive vaccinia, and generalized vaccinia.
CONCLUSIONS: The balance between the risks and benefits of mass vaccination in prevention of an epidemic is not clear. The Centers for Disease Control and Prevention has established a guideline for appropriate use of smallpox vaccine in the civilian population.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14755066     DOI: 10.1345/aph.1D272

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  3 in total

1.  5-(Dimethoxymethyl)-2'-deoxyuridine: a novel gem diether nucleoside with anti-orthopoxvirus activity.

Authors:  Xuesen Fan; Xinying Zhang; Longhu Zhou; Kathy A Keith; Earl R Kern; Paul F Torrence
Journal:  J Med Chem       Date:  2006-06-01       Impact factor: 7.446

2.  Vaccinia virus entry, exit, and interaction with differentiated human airway epithelia.

Authors:  Paola D Vermeer; Julia McHugh; Tatiana Rokhlina; Daniel W Vermeer; Joseph Zabner; Michael J Welsh
Journal:  J Virol       Date:  2007-06-20       Impact factor: 5.103

3.  The proteoglycan bamacan is a host cellular ligand of vaccinia virus neurovirulence factor N1L.

Authors:  Ketha V K Mohan; Cheryl X Zhang; Chintamani D Atreya
Journal:  J Neurovirol       Date:  2009-05       Impact factor: 3.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.